Crabp2 might be a potential prognostic biomarker for lung cancer and a therapeutic target to inhibit metastasis and enhance the inhibitory effects of gemcitabine and irinotecan in metastatic lung cancer cells. The gene discussed is CRABP2; the disease is lung cancer.